Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis / Kilian Friedrich, Carina Baumann, Andreas Wannhoff, Christian Rupp, Arianeb Mehrabi, Karl Heinz Weiss, Daniel N. Gotthardt
BACKGROUND AND AIMS: The disease course of primary sclerosing cholangitis (PSC) is variable and difficult to predict. MicroRNA-122 (miR-122) is associated with various liver diseases. We investigated the value of miR-122 as a biomarker for the disease course of PSC. - METHODS: We determined serum miR-122 levels in a long-term, prospective cohort of 114 PSC patients and a second validation cohort. - RESULTS: Based on miR-122 levels, PSC patients were assigned to low or high level miR-122 groups. Kaplan-Meier analysis showed significantly impaired actuarial transplant-free survival for PSC patients in the low miR-122 group (mean: 46.1 +/- 4.1 months; 95% confidence intervals [CI]: 38.1-54.2) compared to the high miR-122 group (mean: 95.2 +/- 7.9 months; 95% CI: 79.5-110.8; p = 0.034). Using a multivariate Cox's proportional hazards model approach, Mayo-Risk score (odds ratio [OR]: 1.47; 95% CI: 1.13‒1.92; p = 0.004), the presence of dominant strictures (OR: 2.62; 95% CI: 1.00‒5.55; p = 0.004), and serum miR-122 levels (OR: 1.19; 95% CI: 1.00‒1.43; p = 0.045) were independent risk factors associated with reduced actuarial transplant-free survival. We were able to confirm this finding in a second, independent cohort of PSC patients (low miR-122 group: mean survival: 13.1 +/- 5.2 months; 95% CI: 2.8-23.4; high miR-122 group: mean: 28.62 +/- 4.2 months; 95% CI: 20.3-37.0; p = 0.018). - CONCLUSIONS: We identified miR-122 as a novel, independent prognostic biomarker associated with improved survival in PSC patients. It is unknown whether exogenous miR-122 might influence the disease course of PSC patients. ..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of gastrointestinal and liver diseases - 27(2018), 2, Seite 145-150 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Serum miRNA-one hundred twenty-two is an independent biomarker of survival in patients with primary sclerosing cholangitis |
|---|
| Beteiligte Personen: |
Friedrich, Kilian, 1983- [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Gesehen am 10.12.2019 |
|---|
| Umfang: |
7 |
|---|
| doi: |
10.15403/jgld.2014.1121.272.cho |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1684898501 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1684898501 | ||
| 003 | DE-627 | ||
| 005 | 20230427195911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191210s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15403/jgld.2014.1121.272.cho |2 doi | |
| 035 | |a (DE-627)1684898501 | ||
| 035 | |a (DE-599)KXP1684898501 | ||
| 035 | |a (OCoLC)1341280818 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Friedrich, Kilian |d 1983- |e verfasserin |0 (DE-588)140323651 |0 (DE-627)617699089 |0 (DE-576)31642207X |4 aut | |
| 245 | 1 | 0 | |a Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis |c Kilian Friedrich, Carina Baumann, Andreas Wannhoff, Christian Rupp, Arianeb Mehrabi, Karl Heinz Weiss, Daniel N. Gotthardt |
| 246 | 3 | 3 | |a Serum miRNA-one hundred twenty-two is an independent biomarker of survival in patients with primary sclerosing cholangitis |
| 264 | 1 | |c 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.12.2019 | ||
| 520 | |a BACKGROUND AND AIMS: The disease course of primary sclerosing cholangitis (PSC) is variable and difficult to predict. MicroRNA-122 (miR-122) is associated with various liver diseases. We investigated the value of miR-122 as a biomarker for the disease course of PSC. - METHODS: We determined serum miR-122 levels in a long-term, prospective cohort of 114 PSC patients and a second validation cohort. - RESULTS: Based on miR-122 levels, PSC patients were assigned to low or high level miR-122 groups. Kaplan-Meier analysis showed significantly impaired actuarial transplant-free survival for PSC patients in the low miR-122 group (mean: 46.1 +/- 4.1 months; 95% confidence intervals [CI]: 38.1-54.2) compared to the high miR-122 group (mean: 95.2 +/- 7.9 months; 95% CI: 79.5-110.8; p = 0.034). Using a multivariate Cox's proportional hazards model approach, Mayo-Risk score (odds ratio [OR]: 1.47; 95% CI: 1.13‒1.92; p = 0.004), the presence of dominant strictures (OR: 2.62; 95% CI: 1.00‒5.55; p = 0.004), and serum miR-122 levels (OR: 1.19; 95% CI: 1.00‒1.43; p = 0.045) were independent risk factors associated with reduced actuarial transplant-free survival. We were able to confirm this finding in a second, independent cohort of PSC patients (low miR-122 group: mean survival: 13.1 +/- 5.2 months; 95% CI: 2.8-23.4; high miR-122 group: mean: 28.62 +/- 4.2 months; 95% CI: 20.3-37.0; p = 0.018). - CONCLUSIONS: We identified miR-122 as a novel, independent prognostic biomarker associated with improved survival in PSC patients. It is unknown whether exogenous miR-122 might influence the disease course of PSC patients. . | ||
| 650 | 4 | |a Adolescent | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cholangitis, Sclerosing | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Follow-Up Studies | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Kaplan-Meier Estimate | |
| 650 | 4 | |a Liver Transplantation | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a MicroRNAs | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Prospective Studies | |
| 650 | 4 | |a Risk Factors | |
| 650 | 4 | |a Severity of Illness Index | |
| 650 | 4 | |a Young Adult | |
| 700 | 1 | |a Wannhoff, Andreas |d 1983- |e verfasserin |0 (DE-588)1045619833 |0 (DE-627)774667486 |0 (DE-576)39911095X |4 aut | |
| 700 | 1 | |a Rupp, Christian |d 1982- |e verfasserin |0 (DE-588)1023613190 |0 (DE-627)718110765 |0 (DE-576)367149435 |4 aut | |
| 700 | 1 | |a Mehrabi, Arianeb |d 1967- |e verfasserin |0 (DE-588)137664583 |0 (DE-627)594829763 |0 (DE-576)304831263 |4 aut | |
| 700 | 1 | |a Weiss, Karl Heinz |d 1976- |e verfasserin |0 (DE-588)130069531 |0 (DE-627)489615465 |0 (DE-576)297980203 |4 aut | |
| 700 | 1 | |a Gotthardt, Daniel |d 1973- |e verfasserin |0 (DE-588)12903293X |0 (DE-627)387885137 |0 (DE-576)297458027 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of gastrointestinal and liver diseases |d Cluj-Napoca : Soc., 2006 |g 27(2018), 2, Seite 145-150 |h Online-Ressource |w (DE-627)518632555 |w (DE-600)2253255-9 |w (DE-576)281384517 |x 1842-1121 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2018 |g number:2 |g pages:145-150 |g extent:7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15403/jgld.2014.1121.272.cho |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 936 | u | w | |d 27 |j 2018 |e 2 |h 145-150 |g 7 |
| 951 | |a AR | ||
| 952 | |d 27 |j 2018 |e 2 |h 145-150 |g 7 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 3562324103 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 10-12-19 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 3567538853 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 19-12-19 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r http://dx.doi.org/10.15403/jgld.2014.1121.272.cho | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2018 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_7 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_7 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1451555938 |a Friedrich, Kilian | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1469112809 |a Wannhoff, Andreas | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_3 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1469113600 |a Rupp, Christian | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_4 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1484043162 |a Mehrabi, Arianeb | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416740848 |a Chirurgische Universitätsklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_5 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s p |0 (DE-627)1469113848 |a Weiss, Karl Heinz | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |a pos_6 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s p |0 (DE-627)143559181X |a Gotthardt, Daniel | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |a pos_7 | ||